Table 1.
A list of major nucleic acid candidates currently in clinical trials
| Name | Company | Formulation | Nucleic acid | Disease | Target/encoded protein | Clinical trial phase | ID number |
|---|---|---|---|---|---|---|---|
| ARCT-154 | Arcturus Therapeutics, Inc. | LUNAR (LNP) | self-replicating mRNA | COVID-19 vaccine | Spike Protein | Phase 3 | NCT05012943 |
| ARCT-810 | Arcturus Therapeutics, Inc. | LUNAR (LNP) | mRNA | Ornithine Transcarbamylase Deficiency | Ornithine Transcarbamylase (OTC) | Phase 1,2 | NCT04442347 |
| ARCoV | Walvax Biotechnology, Abogen Biosciences | Ionizable lipid | mRNA | COVID-19 vaccine | receptor binding domain (amino acids 319–541) | Phase 3 | NCT04847102 |
| mRNA-1647 | Moderna | Ionizable LNP | mRNA | Cytomegalovirus Infection | CMV gH Pentamer complex and herpesvirus glycoprotein (gB) protein | Phase 3 | NCT05085366 |
| mRNA-1345 | Moderna | Ionizable LNP | mRNA | Respiratory Syncytial Virus | RSV Fusion Protein | Phase 2, 3 | NCT05127434 |
| mRNA-4157 | Moderna/Merck | Ionizable LNP | mRNA | Solid tumors/Melanoma | tumor-associated antigens | Phase 2 | NCT03313778 |
| mRNA-3705 | Moderna | Ionizable LNP | mRNA | Methylmalonic acidemia | human Methylmalonyl-Coenzyme A Mutase (hMUT) | Phase 1, 2 | NCT04899310 |
| mRNA-2416 | Moderna | Ionizable LNP | mRNA | Relapsed/Refractor y solid tumor malignancies lymphoma, Ovarian Cancer | OX40 Ligand (OX40L) | Phase 1, 2 | NCT03323398 |
| mRNA-1273.617 | Moderna | Ionizable LNP | mRNA | COVID-19 delta variant | N/A | Phase 2 | NCT04927065 |
| mRNA-1273 | Moderna | Ionizable LNP | mRNA | COVID-19 | Spike Protein | Phase 3 | NCT04860297 |
| mRNA-5671 | Moderna/Merck | LNP | mRNA | Neoplasms | KRAS | Phase 1 | NCT03948763 |
| BNT112 | BioNTech | RNA-Lipoplex | mRNA | Prostate Cancer | prostatic acid phosphatase (PAP), prostate-specific antigen (PSA), 3 antigens | Phase 1, 2 | NCT04382898 |
| BNT111 | BioNTech | RNA-Lipoplex | mRNA | Advanced Melanoma | NY-ESO-1, MAGE-A3, and TPTE | Phase 2 | NCT04526899 |
| BNT113 | BioNTech | RNA-Lipoplex | mRNA | human papillomavirus 16 (HPV16)+ head and neck cancer | HPV-16 E6 and E7 | Phase 2 | NCT04534205 |
| BNT122 | BioNTech/Genentech | RNA-Lipoplex (RNA-LPX) | mRNA | 1L Melanoma/Adjuvant Colorectal Cancer | N/A | Phase 2 | NCT04486378 |
| BNT151 | BioNTech | LNP | mRNA | Solid Tumors | IL-2 | Phase 1, 2 | NCT04455620 |
| BNT161 | BioNTech/Pfizer | LNP | mRNA | Seasonal Influenza | influenza antigens | Phase 1 | N/A |
| BNT162 | BioNTech/Pfizer | LNP | mRNA | COVID-19 | Spike protein | Phase 4 | NCT05168709 |
| CVnCoV | CureVac AG | Ionizable LNP | mRNA | COVID-19 vaccine | Spike protein | Phase 3 | NCT04652102 |
| CV7202 | CureVac AG | LNP | mRNA | Rabies | Rabies lyssavirus glycoprotein (RABV-G) | Phase 1 | NCT03713086 |
| INT-1B3 | InteRNA | LNP | miRNA | Solid Tumors | miR-193a-3p | Phase 1 | NCT04675996 |
| MiNA | MTL-CEBPA | NOV340 Smarticles | saRNA | Liver Cancer | CCAAT/enhancer-binding protein alpha (CEBPA) | Phase 1 | NCT02716012 |
| Onpattro (patisiran) | Alnylam | LNP | siRNA | ATTR Amyliodosis-Expansion | Transthyretin | Phase 3 | NCT03997383 |